Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 278, Issue 1 22-1, 2000, Pages

  Shetty, Sreerama ^a   Idell, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Messenger ribonucleic acid

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL LEVEL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

EID: 0033962252     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.2000.278.1.l148     Document Type: Article

References (40)

1. Achbarou, A., S. Kaiser, G. Tremblay, L. G. Ste-Marie, P. Brodt, D. Goltzman, and S.A. Rabbani. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54: 2372-2377, 1994.
2. Blasi, F., J. D. Vassalli, and K. Dano. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 104: 801-804, 1987.
3. Bosma, P. J., and T. Kooistra. Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells. J. Biol. Chem. 266: 17845-17849, 1991.
4. Boyd, D., G. Florent, P. Kim, and M. Brattain. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 48: 3112-3116, 1988.
5. Dano, K., P. A. Andreasen, J. Grondahl-Hansen, P. Kristensen, L. S. Nielsen, and L. Skriver. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44: 139-266, 1985.
6. Fattal, P. G., D. J. Schneider, B. E. Sobel, and J. J. Billadello. Posttranscriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J. Biol. Chem. 267: 12412-12415, 1992.
7. Gerwin, B. I., J. Keski-Oja, M. Seddon, J. F. Lechner, and C. C. Harris. TGF-β1 modulation of urokinase and PAI-1 expression in human bronchial epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 259: L262-L269, 1990.
8. Grondahl-Hansen, J., S. G. Hilsenbeck, I. J. Christensen, G. M. Clark, C. K. Osborne, and N. Brunner. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res. Treat. 43: 153-163, 1997.
9. Gyetko, M. R., R. F. Todd, C. C. Wilkinson, and R. G. Sitrin. The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 93: 1380-1387, 1994.
10. Hollas, W., F. Blasi, and D. Boyd. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res. 51: 3690-3695, 1991.
11. Hollas, W., N. Hoosein, L. W. Chung, A. Mazar, J. Henkin, K. Kariko, E. S. Barnathan, and D. Boyd. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb. Haemost. 68: 662-666, 1992.
12. Janicke, F., M. Schmitt, and H. Graeff. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 17: 303-312, 1991.
13. Lijnen, H. R., H. B. Van, and D. Collen. Characterization of the murine plasminogen/urokinase-type plasminogen-activator system. Eur. J. Biochem. 241: 840-848, 1996.
14. Linial, M., N. Gunderson, and M. Groudine. Enhanced transcription of c-myc in bursal lymphoma cells requires continuous protein synthesis. Science 230: 1126-1132, 1985.
15. Liotta, L. A., W. G. Stetler-Stevenson, and P. S. Steeg. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest. 9: 543-551, 1991.
16. Loskutoff, D. J., T. Ny, M. Sawdey, and D. Lawrence. Fibrinolytic system of cultured endothelial cells: regulation by plasminogen activator inhibitor. J. Cell. Biochem. 32: 273-280, 1986.
17. Loskutoff, D. J., M. Sawdey, and J. Mimuro. Type 1 plasminogen activator inhibitor. Prog. Hemost. Thromb. 9: 87-115, 1989.
18. Lund, L. R., V. Ellis, E. Ronne, C. Pyke, and K. Dano. Transcriptional and posttranscriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem. J. 310: 345-352, 1995.
19. Lund, L. R., E. Ronne, A. L. Roldan, N. Behrendt, J. Romer, F. Blasi, and K. Dano. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J. Biol. Chem. 266: 5177-5181, 1991.
20. Mignatti, P., and D. B. Rifkin. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73: 161-195, 1993.
21. Mitchell, R. L., C. Henning-Chubb, E. Huberman, and I. M. Verma. c-Fos expression is neither sufficient nor obligatory for differentiation of monomyelocytes to macrophages. Cell 45: 497-504, 1986.
22. Mitsubayashi, S., T. Akiyama, T. Kurita, K. Okada, H. Bando, T. Sakai, and O. Matsuo. Plasminogen activator in bladder tumors. Urol. Res. 15: 335-339, 1987.
23. Nanbu, R., P.A. Menoud, and Y. Nagamine. Multiple instability-regulating sites in the 3′untranslated region of the urokinase-type plasminogen activator mRNA. Mol. Cell. Biol. 14: 4920-4928, 1994.
24. Ossowski, L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol. 107: 2437-2445, 1988.
25. Ossowski, L., G. Clunie, M. T. Masucci, and F. Blasi. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 115: 1107-1112, 1991.
26. Pedersen, H., N. Brunner, D. Francis, K. Osterlind, E. Ronne, H. H. Hansen, K. Dano, and J. Grondahl-Hansen. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54: 4671-4675, 1994.
27. Pedersen, H., J. Grondahl-Hansen, D. Francis, K. Osterlind, H. H. Hansen, K. Dano, and N. Brunner. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54: 120-123, 1994.
28. Poste, G., and I. J. Fidler. The pathogenesis of cancer metastasis. Nature 283: 139-146, 1980.
29. Raymond, V., J. A. Atwater, and I. M. Verma. Removal of an mRNA destabilizing element correlates with the increased oncogenicity of proto-oncogene fos. Oncogene Res. 5: 1-12, 1989.
30. Saksela, O., and D. B. Rifkin. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. 4: 93-126, 1988.
31. Sawdey, M., T. J. Podor, and D. J. Loskutoff. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J. Biol. Chem. 264: 10396-10401, 1989.
32. Schmitt, M., F. Janicke, and H. Graeff. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul. Fibrinolysis 1: 695-702, 1990.
33. Shaw, G., and R. Kamen. A conserved AU sequence from the 3′untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46: 659-667, 1986.
34. Shetty, S., and S. Idell. A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 274: L871-L882, 1998.
35. Shetty, S., and S. Idell. Posttranscriptional regulation of urokinase receptor gene expression in lung carcinoma and malignant mesothelioma cells in vitro. Mol. Cell Biochem. 199: 189-200, 1999.
36. Shetty, S., A. Kumar, and S. Idell. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol. Cell. Biol. 17: 1075-1083, 1997.
37. Shetty, S., A. Kumar, A. Johnson, S. Pueblitz, and S. Idell. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am. J. Physiol. Lung Cell. Mol. Physiol. 268: L972-L982, 1995.
38. Shetty, S., A. Kumar, A. R. Johnson, S. Pueblitz, D. Holiday, G. Raghu, and S. Idell. Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs. Am. J. Respir. Cell Mol. Biol. 15: 78-87, 1996.
39. Sprengers, E. D., and C. Kluft. Plasminogen activator inhibitors. Blood 69: 381-387, 1987.
40. Vassalli, J. D., A. P. Sappino, and D. Belin. The plasminogen activator/plasmin system. J. Clin. Invest. 88: 1067-1072, 1991.